Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?

Osses DF, Drost FH, Verbeek JFM, Luiting HB, van Leenders GJLH, Bangma CH, Krestin GP, Roobol MJ, Schoots IG.

BJU Int. 2020 Mar 31. doi: 10.1111/bju.15065. [Epub ahead of print]

PMID:
32232921
2.

Clinicopathological characteristics of glomeruloid architecture in prostate cancer.

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Osanto S, Pelger RCM, van Wezel T, van der Poel H, Bekers E, Helleman J, Roobol MJ, van Leenders GJLH.

Mod Pathol. 2020 Feb 20. doi: 10.1038/s41379-020-0507-2. [Epub ahead of print]

PMID:
32080350
3.

Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at radical prostatectomy.

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Roobol MJ, Helleman J, van Leenders GJLH.

Histopathology. 2020 Jan 16. doi: 10.1111/his.14064. [Epub ahead of print]

PMID:
31944367
4.

Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies.

Verhoef EI, Kweldam CF, Kümmerlin IP, Nieboer D, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJLH.

Arch Pathol Lab Med. 2020 Jan 6. doi: 10.5858/arpa.2019-0361-OA. [Epub ahead of print]

PMID:
31904279
5.

Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy.

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.

Am J Surg Pathol. 2020 Feb;44(2):191-197. doi: 10.1097/PAS.0000000000001384.

PMID:
31592799
6.

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).

Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N.

Eur Urol. 2019 Dec;76(6):790-813. doi: 10.1016/j.eururo.2019.09.020. Epub 2019 Oct 3. Review.

PMID:
31587989
7.

Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.

Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.

Eur Urol Oncol. 2020 Feb;3(1):80-91. doi: 10.1016/j.euo.2019.08.014. Epub 2019 Sep 26.

PMID:
31564531
8.

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA.

Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.

9.

Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.

van Leenders GJLH, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoef EI, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ.

Eur Urol. 2020 Feb;77(2):191-198. doi: 10.1016/j.eururo.2019.07.051. Epub 2019 Aug 19.

PMID:
31439369
10.

Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.

Drost FH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, Schoots IG.

Eur Urol. 2020 Jan;77(1):78-94. doi: 10.1016/j.eururo.2019.06.023. Epub 2019 Jul 18. Review.

PMID:
31326219
11.

[Presence of prostate cancer, but absence of active treatment].

Blanker MH, Bangma CH.

Ned Tijdschr Geneeskd. 2019 May 31;163. pii: D3698. Dutch.

PMID:
31187962
12.

Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens.

Hollemans E, Verhoef EI, Bangma CH, Schoots I, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.

Histopathology. 2019 Sep;75(3):338-345. doi: 10.1111/his.13893. Epub 2019 Aug 2.

13.

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG.

Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663. doi: 10.1002/14651858.CD012663.pub2.

PMID:
31022301
14.

Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7).

Henderson DJP, Houslay MD, Bangma CH, Hoffmann R.

Clin Sci (Lond). 2019 Jan 25;133(2):269-286. doi: 10.1042/CS20180519. Print 2019 Jan 31. Review.

15.

Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer.

de Angst IB, Kil PJM, Bangma CH, Takkenberg JJM.

J Geriatr Oncol. 2019 Jul;10(4):653-658. doi: 10.1016/j.jgo.2018.12.003. Epub 2019 Jan 11.

PMID:
30639265
16.

Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer.

Rodríguez-Blanco G, Zeneyedpour L, Duijvesz D, Hoogland AM, Verhoef EI, Kweldam CF, Burgers PC, Smitt PS, Bangma CH, Jenster G, van Leenders GJLH, Dekker LJM, Luider TM.

Oncotarget. 2018 Nov 23;9(92):36444-36456. doi: 10.18632/oncotarget.26342. eCollection 2018 Nov 23.

17.

Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.

Verbeek JFM, Bangma CH, Kweldam CF, van der Kwast TH, Kümmerlin IP, van Leenders GJLH, Roobol MJ.

Urol Oncol. 2019 Feb;37(2):138-144. doi: 10.1016/j.urolonc.2018.11.021. Epub 2018 Dec 7.

PMID:
30528698
18.

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ.

Eur Urol. 2019 Apr;75(4):558-561. doi: 10.1016/j.eururo.2018.10.047. Epub 2018 Nov 2.

PMID:
30396635
19.

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium.

Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29.

PMID:
30385049
20.

Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.

Mod Pathol. 2019 Jan;32(1):139-146. doi: 10.1038/s41379-018-0157-9. Epub 2018 Oct 22.

21.

Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes.

van Dessel LF, Reuvers SHM, Bangma CH, Aluwini S.

Clin Transl Radiat Oncol. 2018 May 29;11:26-32. doi: 10.1016/j.ctro.2018.05.001. eCollection 2018 Jun.

22.

Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.

Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ.

BJU Int. 2018 Dec;122(6):946-958. doi: 10.1111/bju.14358. Epub 2018 Jun 6.

23.

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.

Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders GJLH, Bangma CH, Roobol MJ.

Transl Androl Urol. 2018 Feb;7(1):132-144. doi: 10.21037/tau.2017.12.29.

24.

Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.

Drost FH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, van der Poel HG, Bangma CH, Roobol MJ; PRIAS study group.

Transl Androl Urol. 2018 Feb;7(1):98-105. doi: 10.21037/tau.2017.12.28.

25.

Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.

Pereira-Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ.

Transl Androl Urol. 2018 Feb;7(1):18-26. doi: 10.21037/tau.2017.12.21.

26.

Prostate cancer screening in Europe and Asia.

Zhang K, Bangma CH, Roobol MJ.

Asian J Urol. 2017 Apr;4(2):86-95. doi: 10.1016/j.ajur.2016.08.010. Epub 2016 Sep 4. Review.

27.

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date.

Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

BJU Int. 2018 May;121(5):737-744. doi: 10.1111/bju.14106. Epub 2018 Jan 18.

28.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

29.

Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.

Verhoef EI, Kweldam CF, Kümmerlin IP, Nieboer D, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Histopathology. 2018 Apr;72(5):760-765. doi: 10.1111/his.13427. Epub 2018 Jan 14.

PMID:
29094386
30.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

31.

Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?

Alberts AR, Schoots IG, Bokhorst LP, Drost FH, van Leenders GJ, Krestin GP, Dwarkasing RS, Barentsz JO, Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2018 Mar;73(3):343-350. doi: 10.1016/j.eururo.2017.06.019. Epub 2017 Jun 21.

PMID:
28647216
32.

Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.

Bokhorst LP, Roobol MJ, Bangma CH, van Leenders GJ.

Prostate. 2017 Jul;77(10):1137-1143. doi: 10.1002/pros.23372. Epub 2017 May 24.

PMID:
28543353
33.

Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Kweldam CF, Kümmerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Mod Pathol. 2017 Aug;30(8):1126-1132. doi: 10.1038/modpathol.2017.29. Epub 2017 May 19.

34.
35.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review.

36.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

37.

Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.

Venderbos LDF, Aluwini S, Roobol MJ, Bokhorst LP, Oomens EHGM, Bangma CH, Korfage IJ.

Qual Life Res. 2017 Jun;26(6):1635-1645. doi: 10.1007/s11136-017-1507-7. Epub 2017 Feb 6.

38.

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ.

BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.

39.

Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ, van Leenders GJ.

Eur J Cancer. 2016 Oct;66:26-33. doi: 10.1016/j.ejca.2016.07.012. Epub 2016 Aug 11.

PMID:
27522247
40.

Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.

Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM, Bangma CH, Ng CF.

Int Urol Nephrol. 2016 Oct;48(10):1631-7. doi: 10.1007/s11255-016-1350-8. Epub 2016 Jun 27.

PMID:
27349564
41.

A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.

Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ; PRIAS study group.

Eur Urol. 2016 Dec;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007. Epub 2016 Jun 19.

PMID:
27329565
42.

Active surveillance for prostate cancer: a narrative review of clinical guidelines.

Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ; Movember GAP3 consortium.

Nat Rev Urol. 2016 Mar;13(3):151-67. doi: 10.1038/nrurol.2015.313. Epub 2016 Jan 27. Review.

PMID:
26813955
43.

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.

Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A.

BJU Int. 2016 Sep;118(3):366-71. doi: 10.1111/bju.13410. Epub 2016 Feb 12.

44.

Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.

Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ.

Eur Urol. 2016 Jun;69(6):1129-34. doi: 10.1016/j.eururo.2015.11.018. Epub 2015 Dec 2.

PMID:
26651990
45.

How Often is Biopsy Necessary in Patients with Prostate Cancer on Active Surveillance?

Bruinsma SM, Bokhorst LP, Roobol MJ, Bangma CH.

J Urol. 2016 Jan;195(1):11-2. doi: 10.1016/j.juro.2015.10.061. Epub 2015 Oct 19. No abstract available.

PMID:
26475660
46.

The measurement properties of the five-item International Index of Erectile Function (IIEF-5): a Dutch validation study.

Utomo E, Blok BF, Pastoor H, Bangma CH, Korfage IJ.

Andrology. 2015 Nov;3(6):1154-9. doi: 10.1111/andr.12112. Epub 2015 Oct 9.

47.

Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.

Aluwini S, Busser WM, Alemayehu WG, Boormans JL, Kirkels WJ, Jansen PP, Praag JO, Bangma CH, Kolkman-Deurloo IK.

Radiother Oncol. 2015 Nov;117(2):252-7. doi: 10.1016/j.radonc.2015.09.019. Epub 2015 Sep 22.

PMID:
26409832
48.

Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J.

Clin Cancer Res. 2016 Jan 1;22(1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. Epub 2015 Aug 19. Erratum in: Clin Cancer Res. 2016 Jul 15;22(14):3702.

49.

Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.

Venderbos LD, Roobol MJ, Bangma CH, van den Bergh RC, Bokhorst LP, Nieboer D, Godtman R, Hugosson J, van der Kwast T, Steyerberg EW.

World J Urol. 2016 Feb;34(2):253-60. doi: 10.1007/s00345-015-1628-y. Epub 2015 Jul 10.

50.

Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer.

Duijvesz D, Versluis CY, van der Fels CA, Vredenbregt-van den Berg MS, Leivo J, Peltola MT, Bangma CH, Pettersson KS, Jenster G.

Int J Cancer. 2015 Dec 15;137(12):2869-78. doi: 10.1002/ijc.29664. Epub 2015 Jul 16.

Supplemental Content

Loading ...
Support Center